SEC Form 4 · accession 0001140361-16-070800
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Lasersohn
Director
Period of report
Jun 22, 2016
Accepted (ET)
Jun 24, 2016 · 6:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.61 | Jun 22, 2016 | A | 15,000 | A | — | Jun 22, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.